Aztreonam
Product introduction:
Aztreonam has the characteristics of weak immunogenicity and less cross allergy with penicillins and cephalosporins, so it can be used to replace aminoglycosides in the treatment of aerobic gram-negative bacterial infection in patients with renal impairment; It can also be used for patients allergic to penicillin and cephalosporin under close observation.
Chemical property:
Aztreonam chemical formula C13H17N5O8S2; The molecular weight is 435.43, the appearance is white to grayish white crystal, soluble in dimethylformamide, slightly soluble in methanol, very slightly soluble in ethanol, and almost insoluble in toluene, chloroform or ethyl acetate.
Toxicity classification: poisoning
Flammability hazard characteristics: combustible; Combustion produces toxic NOx and SOX fumes
Indication:
Aztreonam belongs to single ring β- Lactam antibiotics, with most β- Unlike lactam antibiotics, they do not induce bacterial production β- Lactamases are produced by most bacteria at the same time β- Lactamases are highly stable. It is mainly used to treat respiratory system infection, urinary and reproductive system infection (including acute gonorrhea), abdominal infection, skin and soft tissue infection, pre-operative infection prevention, other serious infections, such as sepsis, etc.
Product features:
1. Aztreonam, abbreviated as AZT, is the first single ring used in clinic β- Lactam antibiotics.
2. With most β- Different from lactam antibiotics, aztreonam did not induce bacterial production β- Lactamases are produced by most bacteria at the same time β- Lactamases are highly stable. Therefore, aztreonam is effective when microorganisms are not sensitive to penicillins, cephalosporins, aminoglycosides and other drugs.
3. Aztreonam has fewer adverse drug reactions and lower incidence of allergic reactions than penicillin and cephalosporin, so it is especially suitable for immunocompromised, elderly and penicillin allergic patients.
4. Aztreonam has no nephrotoxic effect on patients with normal renal function, and is safe and effective for severe urinary tract and biliary tract infection.
5. Aztreonam can be used in combination with other antibiotics. When combined with neopenicillin I, o-chloropenicillin, erythromycin or vancomycin, it does not affect the antibacterial activity of these antibiotics against Gram-positive bacteria. It can resist anaerobic infection when combined with metronidazole and clindamycin, and has definite curative effect when combined with aminoglycosides.
Storage conditions: ventilated, low temperature and dry